Friday 6 November 2026 Export MDGL’s income statement to Excel — free account

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.

Revenue: +50.1%
EPS: +147.3%
Free cash flow: +53.5%
Total debt: +0.45%

Quarter to September 2026, against a year earlier

397.03 3.07 −0.77%

Follow MDGL

Alert me

Market cap: $9.3B
P/E: 0.0×
Fwd P/E: −68.8×
Dividend yield: —
F-score: n/a
Altman Z: 10.48
Beneish M: 0.50
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Madrigal Pharmaceuticals, Inc. 10-K filed Feb 19, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed Feb 19, 2026 · accepted 9:09 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 26, 2025: 21 added · 17 removed · 45 modified; 2 with only figures updated; 1 moved without change

Madrigal Pharmaceuticals, Inc. 10-K filed Feb 19, 2026

What changed

Stockrow Weekly